Celldex Therapeutics

Celldex is developing targeted therapeutics to address devastating diseases for which available treatments are inadequate. The Company's pipeline is built from a proprietary portfolio of antibodies and immunomodulators used alone and in strategic combinations to create novel, disease-specific therapies that induce, enhance or suppress the body's immune response.
Company Growth (employees)
Hampton, US
Size (employees)
205 (est)
Celldex Therapeutics was founded in 1983 and is headquartered in Hampton, US

Key People/Management at Celldex Therapeutics

Anthony Marucci

Anthony Marucci

Founder, President & CEO
Tibor Keler

Tibor Keler

Founder, SVP & CSO
Thomas Davis

Thomas Davis

Ronald A. Pepin

Ronald A. Pepin

SVP & Chief Business Officer

Celldex Therapeutics Office Locations

Celldex Therapeutics has offices in Hampton, Branford, Fall River and Needham
Hampton, US (HQ)
220 53 I-78 Frontage Rd
Branford, US
1a 688 E Main St
Fall River, US
UMass Dartmouth Center for Innovation & Entrepreneurship 151 Martine St
Needham, US
119 4th Ave
Show all (4)

Celldex Therapeutics Financials and Metrics

Celldex Therapeutics Financials

Celldex Therapeutics's revenue was reported to be $5.5 m in FY, 2015

Revenue (Q3, 2017)

3.9 m

Net income (Q3, 2017)

(26.4 m)

EBIT (Q3, 2017)

(32 m)

Market capitalization (22-Dec-2017)

368.2 m

Cash (30-Sep-2017)

54.7 m
Celldex Therapeutics's current market capitalization is $368.2 m.
USDFY, 2013FY, 2014FY, 2015FY, 2016


4.1 m3.6 m5.5 m

Revenue growth, %



(81.4 m)(122.4 m)(129.5 m)

EBIT margin, %

USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q2, 2017Q3, 2017


980 k416 k592 k1.1 m2.2 m1 m1.3 m1.4 m2.2 m1.5 m3.8 m3.9 m

R&D expense

20.4 m27.1 m24.1 m26.2 m26.5 m24.7 m27.4 m25.7 m25 m25.8 m25 m

General and administrative expense

3.6 m4.6 m4.8 m5 m8.2 m8.5 m9.3 m7.8 m7 m7.2 m6.5 m

Operating expense total

24.2 m31.9 m29.1 m31.4 m34.9 m33.4 m37 m33.8 m32.2 m36.6 m32.8 m35.9 m
USDFY, 2013FY, 2014FY, 2015FY, 2016


169.4 m28 m72.1 m42.5 m

Accounts Receivable

489 k427 k97 k1.8 m

Current Assets

305.2 m205 m294.9 m195.6 m


10 m10.5 m11.5 m13.2 m
USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2017Q2, 2017Q3, 2017


14.6 m56.9 m40.8 m32.5 m42.5 m66.2 m54.7 m

Current Assets

139.9 m276.8 m255.6 m229.8 m173.5 m160.1 m147.3 m


8.8 m10.2 m10.6 m10.7 m12.4 m12.1 m


9 m9 m9 m9 m91 m91 m91 m
    USDFY, 2013FY, 2014FY, 2015FY, 2016

    Net Income

    (81.6 m)(118.1 m)(127.2 m)(128.5 m)

    Depreciation and Amortization

    1.9 m2.4 m3 m3.1 m

    Accounts Payable

    7.2 m1.5 m4.9 m(5 m)

    Cash From Operating Activities

    (67.7 m)(101.5 m)(98.9 m)(113 m)
    USDQ3, 2013Q1, 2014Q2, 2014Q3, 2014Q1, 2015Q2, 2015Q3, 2015Q1, 2016Q2, 2016Q3, 2016Q1, 2017Q3, 2017

    Net Income

    (23.1 m)(29.9 m)(28.3 m)(28.1 m)(32.4 m)(32 m)(34.7 m)(32 m)(29.6 m)(34.3 m)(26.4 m)

    Accounts Payable

    1.2 m1.7 m3.1 m2 m1.2 m2.6 m706 k1 m2.7 m1.3 m
      USDY, 2017


      19.1 k

      Financial Leverage

      1.5 x
      Show all financial metrics

      Celldex Therapeutics Operating Metrics

      FY, 2016

      Patents Issued

      Show all operating metrics

      Celldex Therapeutics Market Value History

      Celldex Therapeutics's Web-traffic and Trends

      Celldex Therapeutics Company Life and Culture

      You may also be interested in